Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 JCXH-211 clinical trials
Also written JCXH-211.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 JCXH-211 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JCXH-211
- 2
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Immorna Biotherapeutics, Inc. (2) · Duke University (1)
Studies
Open first, then newest update. How each study uses Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 JCXH-211 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid TumorsCompletedPhase 1Immorna Biotherapeutics, Inc.NCT05727839Written as JCXH-211 InjectionHow we know
- Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid TumorsTerminatedPhase 1Immorna Biotherapeutics, Inc.NCT05539157Written as JCXH-211How we know
- Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade GliomaWithdrawnPhase 1Duke UniversityNCT06468605Written as JCXH-211How we know
What changed recently
From the registry's own updates since Oct 23, 2026.
Stopped1
- Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid TumorsTerminatedNov 5, 2026NCT05539157